Chebulinic acid for alternative treatment of vulvovaginal candidiasis by targeting agglutinin-like sequence protein 3 in candida albicans: in silico approach
By: Sharma, K. K
.
Contributor(s): Katiyar, P.
Publisher: Mumbai Indian Journal of Pharmaceutical Science 2021Edition: Vol.83(4), Jul-Aug.Description: 838-847p.Subject(s): PHARMACEUTICSOnline resources: Click here
In:
Indian journal of pharmaceutical sciencesSummary: Chebulinic acid, a chemotaxonamic marker of Terminalia chebula has been described in Ayurveda, Unani
and Homeopathy traditional medicinal system for the treatment of various fungal diseases. Almost 70-80
% of women are currently affected from vulvovaginal candidiasis and the overgrowth of Candida albicans
is the major reason behind it. The aim of the present study was to determine the efficacy of chebulinic acid
in inhibiting adhesion as well as growth of Candida albicans inside the host in comparison with currently
available azole derivatives in the market. The inhibitory effect of chebulinic acid was determined by
spectrophotometric growth curve analysis reflecting 10 % lower minimum inhibitory concentration value
of fluconazole, ketaconazole, itraconazole and chebulinic acid. Virtual docking study was carried out at
catalytic domain of agglutinin-like sequence protein 3 chain A and B respectively, to determine the binding
affinity and its active binding sites. Chebulinic acid exhibited high sensitivity against Candida albicans
with minimum inhibitory concentration of (0.025 μg/ml) followed by ketaconazole (0.05), itraconazole
(0.048) and fluconazole (1.5). An extended lag phase and a decline in overall growth were observed in
Candida albicans when compared to control when grown in presence of chebulinic acid. At ASN22, TYR23,
TRP224, ASP169, TYR166, ASP162, ASN225 GLY297, ARG294 and ASP162, ASN160, ASP169, THR168,
TYR166, TYR226, chebulinic acid binds with agglutinin-like sequence protein 3 chain A and B respectively
with binding affinity of -10.4 and -9.8 kcal/mol. Our present study strengthens the evidences which stand
in support of the fact that chebulinic acid can be used as potent inhibitor of Candida albicans than other
commercially available synthetic anti-fungal drugs.
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2022-0937 |
Chebulinic acid, a chemotaxonamic marker of Terminalia chebula has been described in Ayurveda, Unani
and Homeopathy traditional medicinal system for the treatment of various fungal diseases. Almost 70-80
% of women are currently affected from vulvovaginal candidiasis and the overgrowth of Candida albicans
is the major reason behind it. The aim of the present study was to determine the efficacy of chebulinic acid
in inhibiting adhesion as well as growth of Candida albicans inside the host in comparison with currently
available azole derivatives in the market. The inhibitory effect of chebulinic acid was determined by
spectrophotometric growth curve analysis reflecting 10 % lower minimum inhibitory concentration value
of fluconazole, ketaconazole, itraconazole and chebulinic acid. Virtual docking study was carried out at
catalytic domain of agglutinin-like sequence protein 3 chain A and B respectively, to determine the binding
affinity and its active binding sites. Chebulinic acid exhibited high sensitivity against Candida albicans
with minimum inhibitory concentration of (0.025 μg/ml) followed by ketaconazole (0.05), itraconazole
(0.048) and fluconazole (1.5). An extended lag phase and a decline in overall growth were observed in
Candida albicans when compared to control when grown in presence of chebulinic acid. At ASN22, TYR23,
TRP224, ASP169, TYR166, ASP162, ASN225 GLY297, ARG294 and ASP162, ASN160, ASP169, THR168,
TYR166, TYR226, chebulinic acid binds with agglutinin-like sequence protein 3 chain A and B respectively
with binding affinity of -10.4 and -9.8 kcal/mol. Our present study strengthens the evidences which stand
in support of the fact that chebulinic acid can be used as potent inhibitor of Candida albicans than other
commercially available synthetic anti-fungal drugs.
Click on an image to view it in the image viewer
There are no comments for this item.